Notice of Consultation on the Prescription Drug List (PDL): Epinephrine chloride (topical solution)
From Health Canada
Current status: Open
Opened on August 12, 2019 and will close to new input on October 26, 2019.
This Consultation provides an opportunity to comment on the proposal to add epinephrine topical solution for hemostasis when sold at a concentration equal to or greater than 1 mg/ ml (1:1000) to the Prescription Drug List (PDL).
Join in: how to participate
Send us an email: Send an email to hc.drug.prescription.status-statut.dordonnance.des.drogues.sc@canada.ca with your ideas or comments to make yourself heard.
Participate by mail: Send a letter with your ideas and input to the address in contact information below.
Who is the focus of this consultation
We will engage with:
- Practioners
- Drug manufacturers
Goals of the consultation
Products containing "Epinephrine topical solution for hemostasis when sold at a concentration equal to or greater than 1 mg/ ml (1:1000)" will be considered prescription products under the Food and Drugs Regulations (FDR), and as such, would no longer be considered NHPs.
Contact us
Health Canada
Prescription Drug Status Committee
Address Locator 3102C3
Holland Cross, Tower B
1600 Scott Street
Ottawa, Ontario
K1A 0K9
Email: hc.drug.prescription.status-statut.dordonnance.des.drogues.sc@canada.ca
Telephone: 343-998-9304
Facsimile: 613-941-1812